Medtech industry to work with EMA on notified body role regarding ATMPs
This article was originally published in RAJ Devices
The European Medicines Agency’s Committee for Advanced Therapies is drafting guidance to explain how medical device notified bodies should interact with the EMA when evaluating advanced therapy medical products containing a medical device.
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.